S. Ferrari

发表

Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors.

E. Novellino, F. Da Settimo, C. La Motta, 2018, European journal of medicinal chemistry.

Evaluation of the sensitivity to chemotherapeutics or thiazolidinediones of primary anaplastic thyroid cancer cells obtained by fine-needle aspiration.

E. Ferrannini, F. Basolo, P. Miccoli, 2008, European journal of endocrinology.

Primary cell cultures from anaplastic thyroid cancer obtained by fine‐needle aspiration used for chemosensitivity tests

E. Ferrannini, P. Miccoli, P. Berti, 2008, Clinical endocrinology.

Novel Pyrazolopyrimidine Derivatives as Tyrosine Kinase Inhibitors with Antitumoral Activity in Vitro and in Vivo in Papillary Dedifferentiated Thyroid Cancer

G. Alí, G. Fontanini, R. Danesi, 2011 .

CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo.

G. Alí, G. Fontanini, F. Da Settimo, 2012, The Journal of clinical endocrinology and metabolism.

β (CCL2) and α (CXCL10) chemokine modulations by cytokines and peroxisome proliferator-activated receptor-α agonists in Graves' ophthalmopathy.

E. Ferrannini, S. Gelmini, S. Frascerra, 2012, The Journal of endocrinology.

CXCL9 and CXCL11 chemokines modulation by peroxisome proliferator-activated receptor-alpha agonists secretion in Graves' and normal thyrocytes.

E. Ferrannini, S. Frascerra, A. Antonelli, 2010, The Journal of clinical endocrinology and metabolism.

Th1 chemokines in autoimmune endocrine disorders.

A. Antonelli, S. Ferrari, P. Fallahi, 2019, The Journal of clinical endocrinology and metabolism.

Chemokines in hyperthyroidism

A. Antonelli, S. Ferrari, P. Fallahi, 2019, Journal of clinical & translational endocrinology.

Interferon-alpha, -beta and -gamma induce CXCL9 and CXCL10 secretion by human thyrocytes: modulation by peroxisome proliferator-activated receptor-gamma agonists.

P. Vitti, M. Serio, E. Ferrannini, 2010, Cytokine.

CXCL10 (alpha) and CCL2 (beta) chemokines in systemic sclerosis--a longitudinal study.

E. Ferrannini, S. Frascerra, A. Antonelli, 2008, Rheumatology.

Sorafenib in the treatment of thyroid cancer

P. Miccoli, A. Antonelli, S. Ferrari, 2015, Expert review of anticancer therapy.

Increased serum CXCL10 in Graves' disease or autoimmune thyroiditis is not associated with hyper- or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process.

M. Rotondi, M. Serio, E. Ferrannini, 2006, European journal of endocrinology.

Serum Th1 (CXCL10) and Th2 (CCL2) chemokine levels in children with newly diagnosed Type 1 diabetes: a longitudinal study

G. d’Annunzio, R. Lorini, E. Ferrannini, 2008, Diabetic medicine : a journal of the British Diabetic Association.

Myo-inositol in autoimmune thyroiditis, and hypothyroidism

A. Antonelli, S. Ferrari, P. Fallahi, 2018, Reviews in Endocrine and Metabolic Disorders.

Increased incidence of autoimmune thyroid disorders in patients with psoriatic arthritis: a longitudinal follow-up study

M. Miccoli, A. Antonelli, S. Ferrari, 2017, Immunologic Research.

Circulating CXCL10 is increased in non-segmental vitiligo, in presence or absence of autoimmune thyroiditis.

A. Antonelli, S. Ferrari, P. Fallahi, 2017, Autoimmunity reviews.

Incidence of thyroid disorders in mixed cryoglobulinemia: Results from a longitudinal follow-up.

A. Antonelli, S. Ferrari, P. Fallahi, 2016, Autoimmunity reviews.

Novel Therapies for Thyroid Autoimmune Diseases

S. Benvenga, A. Antonelli, S. Ferrari, 2016, Expert review of clinical pharmacology.

CXCR3, CXCR5, CXCR6, and CXCR7 in Diabetes.

A. Antonelli, S. Ferrari, P. Fallahi, 2016, Current drug targets.

1 CXCR 3 , CXCR 5 , CXCR 6 , and CXCR 7 in Diabetes

A. Antonelli, S. Ferrari, P. Fallahi, 2016 .

The role of human parvovirus B19 and hepatitis C virus in the development of thyroid disorders

S. Benvenga, A. Antonelli, S. Ferrari, 2016, Reviews in Endocrine and Metabolic Disorders.

Application of Agents Against Interferon-Gamma-Dependent Chemokines in Immunotherapy

A. Antonelli, S. Ferrari, P. Fallahi, 2015 .

Vaccinations and Type 1 Diabetes

E. Ferrannini, A. Antonelli, S. Ferrari, 2015 .

CXCL10 in psoriasis.

A. Antonelli, S. Ferrari, P. Fallahi, 2015, Advances in medical sciences.

Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases.

E. Ferrannini, A. Antonelli, S. Ferrari, 2014, Autoimmunity reviews.

CXCR3, CXCL10 and type 1 diabetes.

E. Ferrannini, A. Antonelli, S. Ferrari, 2014, Cytokine & growth factor reviews.

Mini review CXCR 3 , CXCL 10 and type 1 diabetes

E. Ferrannini, A. Antonelli, S. Ferrari, 2014 .

Graves' disease: Epidemiology, genetic and environmental risk factors and viruses.

Y. Shoenfeld, A. Antonelli, S. Ferrari, 2020, Best practice & research. Clinical endocrinology & metabolism.

New Targeted Therapies for Thyroid Cancer

P. Miccoli, F. Santini, A. Antonelli, 2011, Current genomics.

Effect of PPAR-gamma activation and inhibition on glucose-stimulated insulin release in INS-1e cells.

E. Ferrannini, A. Masoni, A. Antonelli, 2004, Diabetes.

Metastases free thyroid cancer patients harbouring TERT mutations may benefit from a more intensive treatment and follow-up.

A. Antonelli, S. Ferrari, P. Fallahi, 2019, Gland surgery.

Hepatitis C virus infection and type 1 and type 2 diabetes mellitus.

E. Ferrannini, A. Antonelli, S. Ferrari, 2014, World journal of diabetes.

Combination Strategies Involving Immune Checkpoint Inhibitors and Tyrosine Kinase or BRAF Inhibitors in Aggressive Thyroid Cancer

A. Antonelli, S. Ferrari, P. Fallahi, 2022, International journal of molecular sciences.

The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer

P. Miccoli, A. Antonelli, S. Ferrari, 2016, Expert review of anticancer therapy.

The Role of Total Thyroidectomy in the Initial Treatment of Well-differentiated Follicular-cell-derived Thyroid Carcinomas

P. Miccoli, A. Antonelli, S. Ferrari, 2010 .

Hepatitis C virus infection: evidence for an association with type 2 diabetes.

E. Ferrannini, A. Antonelli, S. Ferrari, 2005, Diabetes care.

Prevalence of thyroid dysfunctions in systemic lupus erythematosus.

S. Bombardieri, A. Antonelli, S. Ferrari, 2010, Metabolism: clinical and experimental.

Thyroid cancer in systemic lupus erythematosus: a case-control study.

S. Bombardieri, P. Miccoli, A. Antonelli, 2010, The Journal of clinical endocrinology and metabolism.

L-T4 Therapy in Enteric Malabsorptive Disorders

A. Antonelli, S. Ferrari, P. Fallahi, 2021, Frontiers in Endocrinology.

Recent advances in precision medicine for the treatment of anaplastic thyroid cancer

C. La Motta, A. Antonelli, S. Ferrari, 2019, Expert Review of Precision Medicine and Drug Development.

Current and future immunotherapies for thyroid cancer

A. Antonelli, S. Ferrari, P. Fallahi, 2018, Expert review of anticancer therapy.

Oral L‐thyroxine liquid versus tablet in patients submitted to total thyroidectomy for thyroid cancer (without malabsorption): A prospective study

P. Miccoli, A. Antonelli, S. Ferrari, 2018, Laryngoscope investigative otolaryngology.

Advancements in the treatment of hypothyroidism with L-T4 liquid formulation or soft gel capsule: an update

P. Miccoli, A. Antonelli, S. Ferrari, 2017, Expert opinion on drug delivery.

Oral l-thyroxine liquid versus tablet in patients with hypothyroidism without malabsorption: a prospective study

A. Antonelli, S. Ferrari, P. Fallahi, 2016, Endocrine.

The Stability of TSH, and Thyroid Hormones, in Patients Treated With Tablet, or Liquid Levo-Thyroxine

S. Benvenga, A. Antonelli, S. Ferrari, 2021, Frontiers in Endocrinology.

Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer.

C. La Motta, P. Miccoli, S. Sartini, 2015, Mini reviews in medicinal chemistry.

Tyrosine kinase inhibitors for the therapy of anaplastic thyroid cancer

P. Miccoli, A. Antonelli, S. Ferrari, 2015 .

The Covid-19, Epidemiology, Clinic and Prevention

A. Antonelli, S. Ferrari, P. Fallahi, 2020, Current genomics.

Immunomodulation of CXCL 10 Secretion by Hepatitis C Virus : Could CXCL 10 Be a Prognostic Marker of Chronic Hepatitis C ?

A. Antonelli, S. Ferrari, P. Fallahi, 2019 .

Immunomodulation of CXCL10 Secretion by Hepatitis C Virus: Could CXCL10 Be a Prognostic Marker of Chronic Hepatitis C?

A. Antonelli, S. Ferrari, P. Fallahi, 2019, Journal of immunology research.

Thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma in children.

P. Miccoli, P. Berti, A. Antonelli, 2006, Surgery.

The protective effect of myo-inositol on human thyrocytes

S. Benvenga, A. Antonelli, S. Ferrari, 2018, Reviews in Endocrine and Metabolic Disorders.

Favorable effects of myo-inositol, selenomethionine or their combination on the hydrogen peroxide-induced oxidative stress of peripheral mononuclear cells from patients with Hashimoto's thyroiditis: preliminary in vitro studies.

S. Benvenga, A. Antonelli, S. Ferrari, 2017, European review for medical and pharmacological sciences.

The aggregation between AITD with rheumatologic, or dermatologic, autoimmune diseases.

Y. Shoenfeld, S. Camastra, A. Antonelli, 2019, Best practice & research. Clinical endocrinology & metabolism.

Role of CXCL 10 in cryoglobulinaemia

A. Antonelli, S. Ferrari, P. Fallahi, 2015 .

Interferon-α, -β and -γ induce CXCL11 secretion in human thyrocytes: modulation by peroxisome proliferator-activated receptor γ agonists.

E. Ferrannini, A. Antonelli, S. Ferrari, 2013, Immunobiology.

Cytokines and HCV-Related Disorders

D. Sansonno, A. Antonelli, S. Ferrari, 2012, Clinical & developmental immunology.

The Emerging Extrahepatic Manifestations of Hepatitis C Virus Infection in Chronic Hepatitis and Mixed Cryoglobulinemia

D. Sansonno, A. Antonelli, S. Ferrari, 2008 .

Immunopathogenesis of HCV-related endocrine manifestations in chronic hepatitis and mixed cryoglobulinemia.

A. Antonelli, S. Ferrari, P. Fallahi, 2008, Autoimmunity reviews.

Metformin and Heart Failure: Innocent Until Proven Guilty

E. Ferrannini, A. Antonelli, S. Ferrari, 2006 .

Dysregulation of secretion of CXC alpha-chemokine CXCL10 in papillary thyroid cancer: modulation by peroxisome proliferator-activated receptor-gamma agonists.

C. Lupi, F. Basolo, S. Gelmini, 2009, Endocrine-related cancer.

CXCL10 and CCL2 serum levels in patients with mixed cryoglobulinaemia and hepatitis C.

E. Ferrannini, S. Frascerra, A. Antonelli, 2009, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

High values of Th1 (CXCL10) and Th2 (CCL2) chemokines in patients with psoriatic arthtritis.

E. Ferrannini, S. Bombardieri, A. Delle Sedie, 2009, Clinical and experimental rheumatology.

Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves' disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists.

S. S. Franceschini, E. Ferrannini, S. Frascerra, 2009, The Journal of clinical endocrinology and metabolism.

CXCL10 ( a ) and CCL2 ( b ) chemokines in systemic sclerosis—a longitudinal study

E. Ferrannini, S. Frascerra, A. Antonelli, 2007 .

Increase of interferon-gamma inducible alpha chemokine CXCL10 but not beta chemokine CCL2 serum levels in chronic autoimmune thyroiditis.

M. Rotondi, M. Serio, E. Ferrannini, 2005, European journal of endocrinology.

CLINICAL Increase of interferon- g inducible a chemokine CXCL10 but not b chemokine CCL2 serum levels in chronic autoimmune thyroiditis

M. Rotondi, M. Serio, E. Ferrannini, 2005 .

Novel therapies for thyroid autoimmune diseases: An update.

Y. Shoenfeld, S. Camastra, A. Antonelli, 2019, Best practice & research. Clinical endocrinology & metabolism.

Myo-inositol and selenium in subclinical hypothyroidism

A. Antonelli, S. Ferrari, P. Fallahi, 2018 .

Vanadium pentoxide induces the secretion of CXCL9 and CXCL10 chemokines in thyroid cells.

S. Benvenga, A. Antonelli, S. Ferrari, 2018, Oncology reports.

The paramount role of cytokines and chemokines in papillary thyroid cancer: a review and experimental results

S. Gelmini, A. Antonelli, S. Ferrari, 2018, Immunologic Research.

Differential modulation by vanadium pentoxide of the secretion of CXCL8 and CXCL11 chemokines in thyroid cells.

S. Benvenga, A. Antonelli, S. Ferrari, 2018, Molecular medicine reports.

Induction of Th1 chemokine secretion in dermal fibroblasts by vanadium pentoxide.

S. Benvenga, A. Antonelli, S. Ferrari, 2018, Molecular medicine reports.

Associations between Systemic Sclerosis and Thyroid Diseases

A. Antonelli, S. Ferrari, P. Fallahi, 2017, Front. Endocrinol..

The role of the Th1 chemokine CXCL10 in vitiligo.

A. Antonelli, S. Ferrari, P. Fallahi, 2015, Annals of translational medicine.

Extra-ocular muscle cells from patients with Graves' ophthalmopathy secrete α (CXCL10) and β (CCL2) chemokines under the influence of cytokines that are modulated by PPARγ.

S. S. Franceschini, E. Ferrannini, S. Gelmini, 2014, Autoimmunity reviews.

Circulating chemokine (CXC motif) ligand (CXCL)9 is increased in aggressive chronic autoimmune thyroiditis, in association with CXCL10.

M. Miccoli, E. Ferrannini, S. Benvenga, 2011, Cytokine.

Induction of CXCL10 secretion by interferon‐γ and tumour necrosis factor‐α and its inhibition by peroxisome proliferator‐activated receptor‐γ agonists in cultured scleroderma fibroblasts

A. Antonelli, S. Ferrari, P. Fallahi, 2010, The British journal of dermatology.

High Serum Levels of CXCL11 in Mixed Cryoglobulinemia Are Associated with Increased Circulating Levels of Interferon-γ

M. Miccoli, S. Frascerra, A. Antonelli, 2011, The Journal of Rheumatology.

Iodine-131 given for therapeutic purposes modulates differently interferon-gamma-inducible alpha-chemokine CXCL10 serum levels in patients with active Graves' disease or toxic nodular goiter.

G. Mariani, M. Rotondi, M. Serio, 2007, The Journal of clinical endocrinology and metabolism.

High levels of circulating chemokine (C-X-C motif) ligand 11 are associated with euthyroid or subclinically hypothyroid autoimmune thyroiditis and with chemokine (C-X-C motif) ligand 10.

M. Miccoli, P. Miccoli, S. Frascerra, 2012, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists.

S. S. Franceschini, M. Rotondi, M. Serio, 2006, The Journal of clinical endocrinology and metabolism.

Alpha-chemokine CXCL10 and beta-chemokine CCL2 serum levels in patients with hepatitis C-associated cryoglobulinemia in the presence or absence of autoimmune thyroiditis.

E. Ferrannini, A. Nicolini, S. Frascerra, 2008, Metabolism: clinical and experimental.

Peroxisome proliferator-activated receptor α agonists modulate Th1 and Th2 chemokine secretion in normal thyrocytes and Graves' disease.

E. Ferrannini, S. Benvenga, S. Frascerra, 2011, Experimental cell research.

Interferon-γ-Inducible α-Chemokine CXCL10 Involvement in Graves’ Ophthalmopathy: Modulation by Peroxisome Proliferator-Activated Receptor-γ Agonists

S. S. Franceschini, M. Rotondi, M. Serio, 2006 .

Th1 and Th2 chemokine serum levels in systemic sclerosis in the presence or absence of autoimmune thyroiditis.

E. Ferrannini, S. Frascerra, A. Antonelli, 2008, The Journal of rheumatology.

High levels of circulating CXC chemokine ligand 10 are associated with chronic autoimmune thyroiditis and hypothyroidism.

M. Rotondi, M. Serio, E. Ferrannini, 2004, The Journal of clinical endocrinology and metabolism.

Increase of interferon‐γ‐inducible CXC chemokine CXCL10 serum levels in patients with active Graves’ disease, and modulation by methimazole therapy

M. Rotondi, M. Serio, E. Ferrannini, 2006, Clinical endocrinology.

High values of alpha (CXCL10) and beta (CCL2) circulating chemokines in patients with psoriatic arthritis, in presence or absence of autoimmune thyroiditis

E. Ferrannini, S. Bombardieri, A. Antonelli, 2008, Autoimmunity.

Interleukin-1β, C-x-C motif ligand 10, and interferon-gamma serum levels in mixed cryoglobulinemia with or without autoimmune thyroiditis.

A. Antonelli, S. Ferrari, P. Fallahi, 2010, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

Serum levels of the interferon‐γ‐inducible α chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy

M. Rotondi, M. Serio, P. Miccoli, 2006 .

Circulating CXCL11 and CXCL10 are increased in hepatitis C-associated cryoglobulinemia in the presence of autoimmune thyroiditis

A. Antonelli, S. Ferrari, P. Fallahi, 2012, Modern rheumatology.

Systemic Sclerosis Fibroblasts Show Specific Alterations of Interferon-γ and Tumor Necrosis Factor-α-induced Modulation of Interleukin 6 and Chemokine Ligand 2

A. Antonelli, S. Ferrari, P. Fallahi, 2012, The Journal of Rheumatology.

Iodine-131 Given for Therapeutic Purposes Modulates Differently Interferon-γ-Inducible α-Chemokine CXCL10 Serum Levels in Patients with Active Graves’ Disease or Toxic Nodular Goiter

G. Mariani, M. Rotondi, M. Serio, 2007 .

Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy.

M. Rotondi, M. Serio, P. Miccoli, 2006, The British journal of surgery.

Effect of PPAR-γ Activation and Inhibition on Glucose-Stimulated Insulin Release in INS-1e Cells

E. Ferrannini, A. Masoni, A. Antonelli, 2004 .

Association of glomerular hyperfiltration with serum chemokine levels and metabolic features in prepubertal children with overweight/obesity.

C. Andrés-Lacueva, A. Antonelli, S. Ferrari, 2020, Nutrition, metabolism, and cardiovascular diseases : NMCD.

Precision Medicine in Autoimmune Thyroiditis and Hypothyroidism

S. Benvenga, A. Antonelli, S. Ferrari, 2021, Frontiers in Pharmacology.

Myo-inositol and selenium reduce the risk of developing overt hypothyroidism in patients with autoimmune thyroiditis.

S. Benvenga, A. Antonelli, S. Ferrari, 2017, European review for medical and pharmacological sciences.

Increased CXCL9 serum levels in hepatitis C-related mixed cryoglobulinemia, with autoimmune thyroiditis, associated with high levels of CXCL10.

S. Benvenga, A. Antonelli, S. Ferrari, 2013, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

Serum α-Chemokine CXCL10 and β-Chemokine CCL2 Levels in HCV-Positive Cryoglobulinemia

E. Ferrannini, A. Antonelli, S. Ferrari, 2012 .

Endocrine Manifestations of HCV-Positive Cryoglobulinemia

A. Antonelli, S. Ferrari, P. Fallahi, 2012 .

Nutraceuticals in Thyroidology: A Review of in Vitro, and in Vivo Animal Studies

D. Bonofiglio, S. Benvenga, S. Camastra, 2020, Nutrients.

Peroxisome proliferator-activated receptor-α agonists modulate CXCL9 and CXCL11 chemokines in Graves’ ophthalmopathy fibroblasts and preadipocytes

E. Ferrannini, S. Gelmini, P. Miccoli, 2012, Molecular and Cellular Endocrinology.

Incidence of thyroid disorders in systemic sclerosis: results from a longitudinal follow-up.

A. Antonelli, S. Ferrari, P. Fallahi, 2013, The Journal of clinical endocrinology and metabolism.

Clinical and subclinical autoimmune thyroid disorders in systemic sclerosis.

E. Ferrannini, A. Antonelli, S. Ferrari, 2007, European journal of endocrinology.

Myoinositol in Autoimmune Thyroiditis

F. Guarneri, S. Benvenga, A. Antonelli, 2022, Frontiers in Endocrinology.

CCL2 is Modulated by Cytokines and PPAR-γ in Anaplastic Thyroid Cancer.

M. Miccoli, A. Antonelli, S. Ferrari, 2017, Anti-cancer agents in medicinal chemistry.

IP-10 in Autoimmune Thyroiditis

S. Ferrari, P. Fallahi, C. Ferri, 2014, Hormone and Metabolic Research.

Increased risk of papillary thyroid cancer in systemic sclerosis associated with autoimmune thyroiditis.

P. Miccoli, A. Antonelli, S. Ferrari, 2015, Rheumatology.

Age-dependent changes in CXC chemokine ligand 10 serum levels in euthyroid subjects.

M. Rotondi, M. Serio, E. Ferrannini, 2005, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

Endocrine disruptors and thyroid autoimmunity.

S. Benvenga, A. Antonelli, S. Ferrari, 2020, Best practice & research. Clinical endocrinology & metabolism.

Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer.

G. Alí, G. Fontanini, F. Da Settimo, 2011, The Journal of clinical endocrinology and metabolism.

Thyroid disorders induced by checkpoint inhibitors

S. Benvenga, A. Antonelli, S. Ferrari, 2018, Reviews in Endocrine and Metabolic Disorders.

Graves’ Disease Following SARS-CoV-2 Vaccination: A Systematic Review

A. Antonelli, S. Ferrari, P. Fallahi, 2022, Vaccines.

Effect of the COVID-19 pandemic on patients with systemic rheumatic diseases

A. Antonelli, S. Ferrari, P. Fallahi, 2021, The Lancet Rheumatology.

Thyroid dysfunctions induced by tyrosine kinase inhibitors

S. Benvenga, A. Antonelli, S. Ferrari, 2014, Expert opinion on drug safety.

Peroxisome proliferator‐activated receptor γ agonists reduce cell proliferation and viability and increase apoptosis in systemic sclerosis fibroblasts

A. Antonelli, S. Ferrari, P. Fallahi, 2013, The British journal of dermatology.

Psoriasis, Psoriatic Arthritis, and Thyroid Autoimmunity

S. Benvenga, A. Antonelli, S. Ferrari, 2017, Front. Endocrinol..

Increase of interferon-γ inducible CXCL9 and CXCL11 serum levels in patients with active Graves' disease and modulation by methimazole therapy.

E. Ferrannini, A. Antonelli, S. Ferrari, 2013, Thyroid : official journal of the American Thyroid Association.

High Circulating Chemokines (C-X-C Motif) Ligand 9, and (C-X-C Motif) Ligand 11, in Hepatitis C-Associated Cryoglobulinemia

D. Sansonno, S. Frascerra, A. Antonelli, 2013, International journal of immunopathology and pharmacology.

Increase of circulating CXCL9 and CXCL11 associated with euthyroid or subclinically hypothyroid autoimmune thyroiditis.

E. Ferrannini, P. Ferrari, A. Nicolini, 2011, The Journal of clinical endocrinology and metabolism.

Type 1 diabetes and (C-X-C motif) ligand (CXCL) 10 chemokine.

E. Ferrannini, A. Antonelli, S. Ferrari, 2014, La Clinica terapeutica.

THERAPY OF ENDOCRINE DISEASE: Endocrine-metabolic effects of treatment with multikinase inhibitors.

M. Miccoli, S. Benvenga, S. Camastra, 2020, European journal of endocrinology.

Prevalence of hypothyroidism and Graves disease in sarcoidosis.

E. Ferrannini, A. Antonelli, S. Ferrari, 2006, Chest.

Regulatory B Cells in Systemic Sclerosis Isolated or Concomitant With Hashimoto Thyroiditis

A. Antonelli, S. Ferrari, P. Fallahi, 2022, Frontiers in Immunology.

Hashimotos' thyroiditis: Epidemiology, pathogenesis, clinic and therapy.

L. Churilov, A. Antonelli, S. Ferrari, 2019, Best practice & research. Clinical endocrinology & metabolism.

Thyroid Involvement in Hepatitis C Virus-Infected Patients with/without Mixed Cryoglobulinemia

A. Antonelli, S. Ferrari, P. Fallahi, 2017, Front. Endocrinol..

The presence of autoimmune thyroiditis in mixed cryoglobulinemia patients is associated with high levels of circulating interleukin-6, but not of tumor necrosis factor-alpha.

P. Ferrari, A. Nicolini, A. Antonelli, 2011, Clinical and experimental rheumatology.

Graves' disease induced by IFN-β1a therapy: A case report, review of literature and new insights into the pathogenesis.

A. Antonelli, S. Ferrari, P. Fallahi, 2022, Autoimmunity reviews.

Differential modulation of CXCL8 versus CXCL10, by cytokines, PPAR-gamma, or PPAR-alpha agonists, in primary cells from Graves' disease and ophthalmopathy.

S. S. Franceschini, M. Nardi, A. Antonelli, 2019, Autoimmunity reviews.

Graves' disease: Clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy.

Y. Shoenfeld, A. Antonelli, S. Ferrari, 2020, Best practice & research. Clinical endocrinology & metabolism.

Hepatitis C virus infection and development of type 2 diabetes mellitus: Systematic review and meta-analysis of the literature

M. Miccoli, A. Antonelli, S. Ferrari, 2018, Reviews in Endocrine and Metabolic Disorders.

Immune and Inflammatory Cells in Thyroid Cancer Microenvironment

G. Marone, A. Antonelli, S. Ferrari, 2019, International journal of molecular sciences.

Genotoxicity Evaluation of the Soybean Isoflavone Genistein in Human Papillary Thyroid Cancer Cells. Study of Its Potential Use in Thyroid Cancer Therapy

A. Antonelli, S. Ferrari, P. Fallahi, 2019, Nutrition and cancer.

Thyroid autoimmune disorders and cancer.

A. Antonelli, S. Ferrari, P. Fallahi, 2020, Seminars in cancer biology.

The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition

A. Antonelli, S. Ferrari, P. Fallahi, 2019, International journal of molecular sciences.

Primary cell cultures for the personalized therapy in aggressive thyroid cancer of follicular origin.

G. Marone, A. Antonelli, S. Ferrari, 2020, Seminars in cancer biology.

Increased Requirement of Replacement Doses of Levothyroxine Caused by Liver Cirrhosis

S. Benvenga, A. Antonelli, S. Ferrari, 2018, Front. Endocrinol..

Review Article Peroxisome Proliferator-activated Receptor-í Μí»¾ in Thyroid Autoimmunity

S. Benvenga, A. Antonelli, S. Ferrari, 2022 .

Cytokines as Targets of Novel Therapies for Graves’ Ophthalmopathy

M. Miccoli, S. Benvenga, S. Camastra, 2021, Frontiers in Endocrinology.

The association of other autoimmune diseases in patients with autoimmune thyroiditis: Review of the literature and report of a large series of patients.

S. Benvenga, A. Antonelli, S. Ferrari, 2016, Autoimmunity reviews.

Autoimmune thyroid disorders.

Alessandro Antonelli, A. Antonelli, S. Ferrari, 2015, Autoimmunity reviews.

The association of other autoimmune diseases in patients with Graves' disease (with or without ophthalmopathy): Review of the literature and report of a large series.

S. Benvenga, A. Antonelli, S. Ferrari, 2019, Autoimmunity reviews.

Systemic Lupus Erythematosus and Thyroid Autoimmunity

A. Antonelli, S. Ferrari, P. Fallahi, 2017, Front. Endocrinol..

Sarcoidosis and Thyroid Autoimmunity

S. Ferrari, P. Fallahi, P. Fazzi, 2017, Front. Endocrinol..

Thyroid uptake of 67Ga-citrate is associated with thyroid autoimmunity and hypothyroidism in patients with sarcoidosis

G. Mariani, E. Ferrannini, A. Antonelli, 2008, European Journal of Nuclear Medicine and Molecular Imaging.

Endocrine manifestations of hepatitis C virus infection

D. Sansonno, A. Antonelli, S. Ferrari, 2009, Nature Clinical Practice Endocrinology &Metabolism.

Thyroid disorders in chronic hepatitis C virus infection.

M. Rotondi, E. Ferrannini, A. Antonelli, 2006, Thyroid : official journal of the American Thyroid Association.

Parallel increase of circulating CXCL11 and CXCL10 in mixed cryoglobulinemia, while the proinflammatory cytokine IL-6 is associated with high serum Th2 chemokine CCL2

M. Miccoli, D. Sansonno, A. Antonelli, 2013, Clinical Rheumatology.

Serum Concentrations of Interleukin 1ß, CXCL10, and Interferon-γ in Mixed Cryoglobulinemia Associated with Hepatitis C Infection

A. Antonelli, S. Ferrari, P. Fallahi, 2010, The Journal of Rheumatology.

Cryoglobulinemia Associated with Hepatitis C Infection in Mixed γ Serum Concentrations of Interleukin 1 ß , CXCL 10 , and Interferon -

A. Antonelli, S. Ferrari, P. Fallahi, 2009 .

High Values of CXCL10 Serum Levels in Mixed Cryoglobulinemia Associated With Hepatitis C Infection

E. Ferrannini, S. Frascerra, A. Antonelli, 2008, The American Journal of Gastroenterology.

Sunitinib in the Treatment of Thyroid Cancer.

M. Miccoli, P. Ferrari, A. Antonelli, 2019, Current medicinal chemistry.

Advances in pharmacotherapy for advanced thyroid cancer of follicular origin (PTC, FTC). New approved drugs and future therapies

S. Benvenga, A. Antonelli, S. Ferrari, 2022, Expert opinion on pharmacotherapy.

RET TKI: Potential Role in Thyroid Cancers

L. Santarpia, A. Antonelli, S. Ferrari, 2012, Current Oncology Reports.

Antineoplastic Effects of PPARγ Agonists, with a Special Focus on Thyroid Cancer.

P. Miccoli, A. Antonelli, S. Ferrari, 2016, Current medicinal chemistry.

Molecular targets of tyrosine kinase inhibitors in thyroid cancer.

S. Benvenga, A. Antonelli, S. Ferrari, 2020, Seminars in cancer biology.

TSH Normalization in Bariatric Surgery Patients After the Switch from l-Thyroxine in Tablet to an Oral Liquid Formulation

S. Benvenga, S. Camastra, A. Antonelli, 2016, Obesity Surgery.

Novel treatments for anaplastic thyroid carcinoma.

C. La Motta, S. Benvenga, A. Antonelli, 2020, Gland surgery.

Novel treatment options for anaplastic thyroid cancer

M. Miccoli, A. Antonelli, S. Ferrari, 2017, Expert review of endocrinology & metabolism.

Protective Effects of Myo-Inositol and Selenium on Cadmium-Induced Thyroid Toxicity in Mice

N. Irrera, L. Minutoli, D. Altavilla, 2020, Nutrients.

Teprotumumab for the treatment of thyroid eye disease

S. Benvenga, A. Antonelli, S. Ferrari, 2023, Expert opinion on biological therapy.

Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes

A. Antonelli, S. Ferrari, P. Fallahi, 2019, Cancer management and research.

Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes

A. Antonelli, S. Ferrari, P. Fallahi, 2019 .

Thyroid-associated ophthalmopathy and TSH receptor autoantibodies in nonmetastatic thyroid cancer after total thyroidectomy.

E. Ferrannini, A. Antonelli, S. Ferrari, 2008, The American journal of the medical sciences.

Personalization of Targeted Therapy in Advanced Thyroid Cancer

S. Benvenga, A. Antonelli, S. Ferrari, 2014, Current genomics.

The paramount role of cytokines and chemokines in papillary thyroid cancer: a review and experimental results

S. Gelmini, A. Antonelli, S. Ferrari, 2018, Immunologic Research.

Sorafenib and Thyroid Cancer

P. Miccoli, F. Santini, A. Antonelli, 2013, BioDrugs.

Thyroid cancer in HCV-related chronic hepatitis patients: a case-control study.

E. Ferrannini, A. Antonelli, S. Ferrari, 2007, Thyroid : official journal of the American Thyroid Association.

New insight in endocrine-related adverse events associated to immune checkpoint blockade.

A. Antonelli, S. Ferrari, P. Fallahi, 2019, Best practice & research. Clinical endocrinology & metabolism.

Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies

G. Marone, A. Antonelli, S. Ferrari, 2019, International journal of molecular sciences.

Precision Medicine in Graves’ Disease and Ophthalmopathy

S. Benvenga, A. Antonelli, S. Ferrari, 2021, Frontiers in Pharmacology.

Environmental Issues in Thyroid Diseases

S. Benvenga, A. Antonelli, S. Ferrari, 2017, Front. Endocrinol..

A case of Graves' disease and type 1 diabetes mellitus following SARS-CoV-2 vaccination

A. Antonelli, S. Ferrari, P. Fallahi, 2021, Journal of Autoimmunity.

Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo.

C. La Motta, P. Miccoli, A. Antonelli, 2018, Oncology reports.

CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo.

G. Fontanini, F. Da Settimo, C. La Motta, 2014, The Journal of clinical endocrinology and metabolism.

Autoimmune and Neoplastic Thyroid Diseases Associated with Hepatitis C Chronic Infection

A. Antonelli, S. Ferrari, P. Fallahi, 2014, International journal of endocrinology.

Cytokines and HCV-related autoimmune disorders

A. Antonelli, S. Ferrari, P. Fallahi, 2014, Immunologic Research.

Cytokines and HCV-related autoimmune disorders

A. Antonelli, S. Ferrari, P. Fallahi, 2014, Immunologic Research.

Dedifferentiated thyroid cancer: a therapeutic challenge.

P. Miccoli, P. Berti, A. Antonelli, 2008, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoral activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation

P. Miccoli, A. Antonelli, S. Ferrari, 2016, Endocrine.

Cytokines (interferon-γ and tumor necrosis factor-α)-induced nuclear factor-κB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone.

Alessandro Antonelli, Aldo Paolicchi, S. S. Franceschini, 2011, Metabolism: Clinical and Experimental.

New Therapies for Dedifferentiated Papillary Thyroid Cancer

S. Benvenga, P. Miccoli, A. Antonelli, 2015, International journal of molecular sciences.

New Targeted Molecular Therapies for Dedifferentiated Thyroid Cancer

A. Antonelli, S. Ferrari, P. Fallahi, 2010, Journal of oncology.

Molecular testing in the diagnosis of differentiated thyroid carcinomas.

F. Basolo, P. Miccoli, A. Antonelli, 2018, Gland surgery.

High interleukin-6 and tumor necrosis factor-alpha serum levels in hepatitis C infection associated or not with mixed cryoglobulinemia

A. Antonelli, S. Ferrari, P. Fallahi, 2009, Clinical Rheumatology.

Synergistic efficacy of irinotecan and sunitinib combination in preclinical models of anaplastic thyroid cancer.

G. Alí, G. Fontanini, G. Francia, 2017, Cancer letters.

High levels of circulating N‐terminal pro‐brain natriuretic peptide in patients with hepatitis C

S. Ferrari, F. Goglia, M. Sebastiani, 2010, Journal of viral hepatitis.

High circulating levels of N‐terminal pro‐brain natriuretic peptide and interleukin 6 in patients with mixed cryoglobulinemia

A. Antonelli, S. Ferrari, P. Fallahi, 2010, Journal of medical virology.

Antineoplastic Activity of Pazopanib in Anaplastic Thyroid Cancer in Primary Culture

C. La Motta, A. Antonelli, S. Ferrari, 2023, International journal of molecular sciences.

Antineoplastic Effect of Lenvatinib and Vandetanib in Primary Anaplastic Thyroid Cancer Cells Obtained From Biopsy or Fine Needle Aspiration

C. La Motta, A. Antonelli, S. Ferrari, 2018, Front. Endocrinol..

Molecular Targeted Therapies of Aggressive Thyroid Cancer

P. Miccoli, A. Antonelli, S. Ferrari, 2015, Front. Endocrinol..

Chemokines in thyroid autoimmunity.

M. Ghionzoli, A. Antonelli, S. Ferrari, 2023, Best practice & research. Clinical endocrinology & metabolism.

Reversible normalisation of serum TSH levels in patients with autoimmune atrophic gastritis who received L-T4 in tablet form after switching to an oral liquid formulation: a case series

S. Ferrari, P. Fallahi, I. Ruffilli, 2016, BMC Gastroenterology.

Patients with lactose intolerance absorb liquid levothyroxine better than tablet levothyroxine

A. Antonelli, S. Ferrari, P. Fallahi, 2017, Endocrine.

A. Antonelli, S. Ferrari, P. Fallahi, 2013, La Clinica terapeutica.

Worsening of Graves' ophthalmopathy after SARS-CoV-2 mRNA vaccination

A. Antonelli, S. Ferrari, P. Fallahi, 2022, Autoimmunity Reviews.

High prevalence of thyroid autoimmunity and hypothyroidism in patients with psoriatic arthritis.

E. Ferrannini, S. Bombardieri, A. Delle Sedie, 2006, The Journal of rheumatology.

Hepatitis C is Associated with High Levels of Circulating N-Terminal Pro-Brain Natriuretic Peptide and Interleukin-6

A. Antonelli, S. Ferrari, P. Fallahi, 2012 .

N-terminal pro-brain natriuretic peptide and tumor necrosis factor-alpha both are increased in patients with Hepatitis C.

E. Ferrannini, D. Sansonno, A. Antonelli, 2010, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

High circulating N-terminal pro-brain natriuretic peptide and tumor necrosis factor-alpha in mixed cryoglobulinemia.

A. Antonelli, S. Ferrari, P. Fallahi, 2009, World journal of gastroenterology.

Cabozantinib in Thyroid Cancer.

S. Benvenga, P. Miccoli, A. Antonelli, 2015, Recent patents on anti-cancer drug discovery.

Selective use of vandetanib in the treatment of thyroid cancer

S. Benvenga, P. Miccoli, A. Antonelli, 2015, Drug design, development and therapy.

Molecular features of aggressive thyroid cancer

S. Benvenga, A. Antonelli, S. Ferrari, 2022, Frontiers in Oncology.

Increase of CXC chemokine CXCL10 and CC chemokine CCL2 serum levels in normal ageing.

Alessandro Antonelli, Aldo Paolicchi, M. Rotondi, 2006, Cytokine.

Sorafenib and Thyroid Cancer

P. Miccoli, F. Santini, A. Antonelli, 2013, BioDrugs.

Serum levels of proinflammatory cytokines interleukin-1beta, interleukin-6, and tumor necrosis factor alpha in mixed cryoglobulinemia.

A. Antonelli, S. Ferrari, P. Fallahi, 2009, Arthritis and rheumatism.

Chemokines in the Pathogenesis and as Therapeutical Markers and Targets of HCV Chronic Infection and HCV Extrahepatic Manifestations.

A. Antonelli, S. Ferrari, P. Fallahi, 2017, Current drug targets.

Thyroid Metastasis from Primary Breast Cancer

A. Proietti, S. Benvenga, A. Antonelli, 2023, Journal of clinical medicine.

New targeted therapies for anaplastic thyroid cancer.

P. Miccoli, M. D'armiento, F. Santini, 2012, Anti-cancer agents in medicinal chemistry.

High Serum Levels of CXC (CXCL10) and CC (CCL2) Chemokines in Untreated Essential Hypertension

S. Taddei, L. Ghiadoni, E. Ferrannini, 2012, International journal of immunopathology and pharmacology.

CXCL10 and CCL2 chemokine serum levels in patients with hepatitis C associated with autoimmune thyroiditis.

E. Ferrannini, A. Nicolini, S. Frascerra, 2009, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

High serum levels of CXC chemokine ligand 10 in untreated essential hypertension

M. Rotondi, L. Ghiadoni, M. Serio, 2008, Journal of Human Hypertension.

High values of CXCL10 serum levels in patients with hepatitis C associated mixed cryoglobulinemia in presence or absence of autoimmune thyroiditis.

E. Ferrannini, S. Frascerra, A. Antonelli, 2008, Cytokine.

Aggressive thyroid cancer: targeted therapy with sorafenib.

M. Miccoli, P. Miccoli, A. Antonelli, 2017, Minerva endocrinologica.

UV light increases vitamin C uptake by bovine lens epithelial cells.

S. Ferrari, A. Corti, A. Paolicchi, 2004, Molecular vision.

COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study

M. Miccoli, A. Della Rossa, C. Campochiaro, 2021, The Lancet Rheumatology.

Thyroid involvement in hepatitis C — Associated mixed cryoglobulinemia

A. Antonelli, S. Ferrari, P. Fallahi, 2014, Hormones.

Thyroid autoimmunity and SARS-CoV-2 infection: Report of a large Italian series

A. Antonelli, S. Ferrari, P. Fallahi, 2022, Autoimmunity Reviews.

Prevalence and death rate of COVID-19 in systemic autoimmune diseases in the first three pandemic waves. Relationship to disease subgroups and ongoing therapies.

M. Miccoli, F. Cacciapaglia, C. Campochiaro, 2022, Current pharmaceutical design.

Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments.

M. Miccoli, F. Cacciapaglia, C. Campochiaro, 2021, Current pharmaceutical design.

Antineoplastic activity of the multitarget tyrosine kinase inhibitors CLM3 and CLM94 in medullary thyroid cancer in vitro.

F. Da Settimo, C. La Motta, R. Danesi, 2014, Surgery.

IN PATIENTS WITH SUBCLINICAL HYPOTHYROIDISM WHILE IN THERAPY WITH TABLET L-T4, THE LIQUID L-T4 FORMULATION IS MORE EFFECTIVE IN RESTORING EUTHYROIDISM.

A. Antonelli, S. Ferrari, P. Fallahi, 2017, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

POS1246 COVID-19 IN ITALIAN PATIENTS WITH RHEUMATIC AUTOIMMUNE SYSTEMIC DISEASES: RESULTS OF A NATIONWIDE SURVEY STUDY

M. Miccoli, C. Campochiaro, L. Dagna, 2021, Annals of the Rheumatic Diseases.

Thiazolidinediones and antiblastics in primary human anaplastic thyroid cancer cells

E. Ferrannini, F. Basolo, P. Miccoli, 2009, Clinical endocrinology.

Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo.

C. La Motta, P. Miccoli, A. Antonelli, 2018, Oncology reports.

Lenvatinib: an investigational agent for the treatment of differentiated thyroid cancer

C. La Motta, M. Miccoli, S. Benvenga, 2021, Expert opinion on investigational drugs.

Patients with Mixed Cryoglobulinemia and HCV Infection, in Presence or Absence of Autoimmune Thyroiditis, Have High Serum Levels of (CXC MOTIF) Ligand (CXCL)9 and CXCL11 Chemokines

D. Sansonno, S. Frascerra, S. Ferrari, 2012 .

Chemokine (CXC motif) ligand 9 serum levels in mixed cryoglobulinaemia are associated with circulating levels of IFN-gamma and TNF-alpha.

M. Miccoli, E. Ferrannini, S. Frascerra, 2012, Clinical and experimental rheumatology.